EMBARGOED FOR RELEASE UNTIL 4 PM ET, August 05, 2026

Most people with atypical Alzheimer’s may be ineligible for new therapies

Up to 85% would not meet treatment criteria, researchers find

Highlights:

• A new study found that up to 85% of people with atypical Alzheimer’s, variants of the disease that affect thinking, language or vision rather than memory first, may not qualify for newer treatments.

• The study looked at whether people with posterior cortical atrophy, logopenic variant primary progressive aphasia, dysexecutive Alzheimer’s disease and corticobasal syndrome would qualify.

• Many of these people were still in early stages of their disease.
• The study found that current criteria for anti-amyloid therapies may not fit atypical forms of Alzheimer’s disease.
• Researchers say treatment criteria for anti-amyloid therapies should better reflect different Alzheimer’s symptoms.

MINNEAPOLIS —  Many people with less common forms of Alzheimer's disease may not qualify for newer anti-amyloid treatments designed to slow the disease, according to a study published August 5, 2026, in , the medical journal of the .

Researchers found that the majority of people with atypical Alzheimer’s disease, or forms that affect thinking, language or vision rather than memory first, would not meet eligibility criteria for treatment for Alzheimer’s disease called anti-amyloid therapies. These therapies are given early in the disease, often at the first sign of memory problems.

“Atypical Alzheimer’s disease is often underrecognized and underrepresented in clinical trials,” said study author Dror Shir, MD, of the Mayo Clinic in Jacksonville, Florida and a member of the American Academy of Neurology. “Our findings suggest that treatment criteria may unintentionally exclude many of these patients, even when they are in the early stages of disease.”

For the study, researchers looked at 184 people with atypical Alzheimer’s disease confirmed by medical tests. Their first symptoms were not mainly memory problems.

Participants had one of the following types of atypical Alzheimer’s disease: posterior cortical atrophy, which affects vision and spacial awareness; logopenic variant primary progressive aphasia, which affects communication and language; dysexecutive Alzheimer’s disease, which affects planning and problem-solving; or corticobasal syndrome, which affects movement and thinking.

Researchers evaluated whether participants would qualify for the anti-amyloid therapies lecanemab and donanemab based on criteria used in major clinical trials and recommendations created for these drugs.

Researchers found that between 70% and 85% of participants with atypical Alzheimer’s disease would not meet eligibility requirements.

The most common reason for exclusion was poor performance on cognitive screening tests, accounting for 50–67% of exclusions. Shir noted that people with atypical Alzheimer’s disease may have lower scores on tests of visual-spatial abilities or executive functioning even though they are still functioning relatively well with daily activities.

Even though most people in the study were still in the early stages of the disease and could do many daily activities, many did not qualify for the treatments because they scored poorly on thinking tests.

The study found most patients did not meet eligibility criteria due to poor scores on the Mini-Mental State Examination, a 11-question screening test. Other reasons for exclusion included brain imaging findings, excluding 22% to 27% of participants, and disease severity, with 19% to 23% having moderate or severe dementia.

“These results suggest a mismatch between how we measure disease severity and how atypical Alzheimer’s disease presents,” Shir said. “Current tools might overestimate the functional stage of the disease.”

A limitation of the study was that it was retrospective and based on existing clinical data, meaning researchers estimated eligibility rather than evaluating patients directly.

The study was supported by the National Institutes of Health and the Alzheimer’s Association.

Discover more about dementia at, from the ��ɫ����. This resource also offers a website, podcast, and books that connect patients, caregivers and anyone interested in brain health with the most trusted information, straight from the world’s leading experts in brain health. Follow Brain & Life on , , and .

The ��ɫ���� is the leading voice in brain health. As the world’s largest association of neurologists and neuroscience professionals with more than 44,000 members, the AAN provides access to the latest news, science and research affecting neurology for patients, caregivers, physicians and professionals alike. The AAN’s mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor who specializes in the diagnosis, care and treatment of brain, spinal cord and nervous system diseases such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine.

Explore the latest in neurological disease and brain health, from the minds at the AAN at or find us on , , , and .